PT944396E - Composicoes e processos para melhorar o funcionamento gastrointestinal - Google Patents

Composicoes e processos para melhorar o funcionamento gastrointestinal

Info

Publication number: PT944396E
Authority: PT; Portugal
Prior art keywords: glp; compositions; processes; improving gastrointestinal; growth
Prior art date: 1996-12-10

Application number

PT97946986T

Other languages

English (en)

Inventor

Daniel J Drucker

Original Assignee

Ontario Inc 1149336

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-10

Filing date

1997-12-10

Publication date

2003-07-31

1997-12-10 Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336

2003-07-31 Publication of PT944396E publication Critical patent/PT944396E/pt

Links

230000002496 gastric effect Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 3
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 3
239000000813 peptide hormone Substances 0.000 abstract 3
210000002429 large intestine Anatomy 0.000 abstract 2
210000000813 small intestine Anatomy 0.000 abstract 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
235000016709 nutrition Nutrition 0.000 abstract 1
208000030212 nutrition disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT97946986T 1996-12-10 1997-12-10 Composicoes e processos para melhorar o funcionamento gastrointestinal PT944396E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/763,177 US5952301A (en)	1996-12-10	1996-12-10	Compositions and methods for enhancing intestinal function

Publications (1)

Publication Number	Publication Date
PT944396E true PT944396E (pt)	2003-07-31

Family

ID=25067085

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97946986T PT944396E (pt)	1996-12-10	1997-12-10	Composicoes e processos para melhorar o funcionamento gastrointestinal

Country Status (10)

Country	Link
US (1)	US5952301A (pt)
EP (1)	EP0944396B1 (pt)
AT (1)	ATE233096T1 (pt)
AU (1)	AU5220098A (pt)
CA (1)	CA2274596C (pt)
DE (1)	DE69719360T2 (pt)
DK (1)	DK0944396T3 (pt)
ES (1)	ES2193406T3 (pt)
PT (1)	PT944396E (pt)
WO (1)	WO1998025644A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
DK0981362T3 (da) *	1997-05-16	2004-03-15	Ontario Inc 1149336	Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
WO1999038501A2 (en)	1998-02-02	1999-08-05	Trustees Of Tufts College	Method of regulating glucose metabolism, and reagents related thereto
AU7421598A (en) *	1998-05-11	1999-11-29	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
CA2339537A1 (en) *	1998-08-21	2000-03-02	Barbara Wallner	Regulation of substrate activity
US6979697B1 (en)	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
GB9906714D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for improving fertility
GB9906715D0 (en)	1999-03-23	1999-05-19	Ferring Bv	Compositions for promoting growth
EP1806138A1 (en) *	1999-05-25	2007-07-11	Point Therapeutics, Inc.	Anti-tumor agents comprising boroproline compounds
US6890904B1 (en)	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
AU781897B2 (en) *	1999-05-25	2005-06-23	Point Therapeutics, Inc.	Anti-tumor comprising boroproline compounds
AU1130501A (en) *	1999-11-03	2001-05-14	Novo Nordisk A/S	Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
WO2001032199A1 (en)	1999-11-05	2001-05-10	Rogoff Joseph A	Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) *	1999-12-30	2000-02-23	Nps Allelix Corp	GLP-2 formulations
US7371721B2 (en) *	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US20070135345A1 (en) *	2000-09-18	2007-06-14	Henriksen Dennis B	Use of GLP-2 for the treatment or prevention, of bone-related disorders
US20080249016A1 (en) *	2000-09-18	2008-10-09	Sanos Bioscience A/S	Use of GLP-2 in a combination treatment for bone-related disorders
PT1326630E (pt)	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
PT1360202E (pt) *	2001-02-16	2008-09-01	Conjuchem Biotechnologies Inc	Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
WO2003045228A2 (en) *	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
EP1469873A4 (en) *	2001-11-26	2007-10-03	Tufts College	PEPTIDOMIMETIC INHIBITORS FROM BEHIND PROLIN SPLENDING ENZYMES
US20040038864A1 (en) *	2002-06-27	2004-02-26	Per Balschmidt	Use of dimethyl sulfone as isotonicity agent
US7411039B2 (en) *	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
US20080026077A1 (en) *	2002-11-12	2008-01-31	John Hilfinger	Methods and compositions of gene delivery agents for systemic and local therapy
US20050026859A1 (en) *	2002-11-12	2005-02-03	John Hilfinger	Methods and compositions of gene delivery agents for systemic and local therapy
US7767828B2 (en) *	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) *	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2524916T3 (es) *	2003-11-12	2014-12-15	Sino-Med International Alliance, Inc.	Compuestos heterocíclicos de ácido borónico
US7576121B2 (en) *	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2573209A1 (en) *	2004-07-14	2006-01-19	Novartis Ag	Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors
NZ562943A (en)	2005-05-04	2011-03-31	Zealand Pharma As	Glucagon-like-peptide-2 (glp-2) analogues
US7825139B2 (en) *	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
NZ597554A (en)	2006-11-08	2014-04-30	Zealand Pharma As	Selective glucagon-like-peptide-2 (glp-2) analogues
US20110295151A1 (en) *	2010-05-26	2011-12-01	Bakos Gregory J	Enteroendocrine Manipulation for Metabolic Effect
BR112014027345A2 (pt)	2012-05-03	2019-09-03	Zealand Pharma As	análogos de peptídeo 2 semelhante ao glucagon (glp-2)
ES2913946T3 (es)	2013-07-08	2022-06-06	The Univ Of Utah Research Foundation	Péptido y su uso en el tratamiento de trastornos inflamatorios
CN106167789B (zh) *	2015-05-21	2020-08-04	中国科学院上海营养与健康研究所	低氧处理的间充质干细胞及其应用
CN106589110B (zh) *	2015-10-15	2020-01-17	上海迈迹生物医药科技有限公司	包含聚合物和glp-2衍生物的缀合物
JP6563614B1 (ja)	2016-12-09	2019-08-21	ジーランド・ファーマ・ア／エス	アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3614427B2 (ja) *	1991-10-07	2005-01-26	ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド	消化管吸収を増大する方法
NZ243071A (en) *	1992-06-08	1994-09-27	Kabi Pharmacia Ab	Igf-2 (or analogue) compositions for pharmaceutical uses
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
DE69716905T2 (de) *	1996-04-12	2003-07-24	1149336 Ontario Inc., Toronto	Analoge des glucagon ähnlichen peptides -2

1996
- 1996-12-10 US US08/763,177 patent/US5952301A/en not_active Expired - Lifetime
1997
- 1997-12-10 PT PT97946986T patent/PT944396E/pt unknown
- 1997-12-10 CA CA002274596A patent/CA2274596C/en not_active Expired - Fee Related
- 1997-12-10 EP EP97946986A patent/EP0944396B1/en not_active Expired - Lifetime
- 1997-12-10 WO PCT/CA1997/000945 patent/WO1998025644A1/en active IP Right Grant
- 1997-12-10 AU AU52200/98A patent/AU5220098A/en not_active Abandoned
- 1997-12-10 ES ES97946986T patent/ES2193406T3/es not_active Expired - Lifetime
- 1997-12-10 DE DE69719360T patent/DE69719360T2/de not_active Expired - Lifetime
- 1997-12-10 AT AT97946986T patent/ATE233096T1/de active
- 1997-12-10 DK DK97946986T patent/DK0944396T3/da active

Also Published As

Publication number	Publication date
EP0944396B1 (en)	2003-02-26
ES2193406T3 (es)	2003-11-01
WO1998025644A1 (en)	1998-06-18
EP0944396A1 (en)	1999-09-29
AU5220098A (en)	1998-07-03
ATE233096T1 (de)	2003-03-15
DE69719360T2 (de)	2003-12-04
CA2274596C (en)	2004-11-09
CA2274596A1 (en)	1998-06-18
DE69719360D1 (de)	2003-04-03
DK0944396T3 (da)	2003-06-23
US5952301A (en)	1999-09-14

Publication	Publication Date	Title
PT944396E (pt)	2003-07-31	Composicoes e processos para melhorar o funcionamento gastrointestinal
ES2527760T3 (es)	2015-01-29	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1231218A3 (en)	2002-10-30	An appetite-suppressing peptide, its compositions and use
DE69736634D1 (de)	2006-10-19	Antagonisten des intestinotrophen glp-2 peptides
ATE280826T1 (de)	2004-11-15	Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
HK1030160A1 (en)	2001-04-27	Methods of enhancing functioning of the upper gastrointestinal tract
WO1998033509A3 (en)	1999-03-11	Useful properties of human lactoferrin and variants thereof
NL300243I2 (nl)	2007-02-01	Proteïne formuleringen.
WO2004027064A3 (en)	2004-11-18	Ghrh analogues
WO2003000242A3 (en)	2003-05-01	Method for the treatment of lymphedema using guaifenesin
NO973884D0 (no)	1997-08-22	Aminosyrepreparater og anvendelse derav for klinisk ernæring
EP0797999A3 (en)	2002-09-25	Formulations of obesity protein
BR0009472A (pt)	2001-11-27	Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ATE234111T1 (de)	2003-03-15	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
SE9603725D0 (sv)	1996-10-11	New teatment
MXPA05009135A (es)	2005-10-20	Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
BR0213536A (pt)	2004-10-19	Formulações de xarope de ribavirina
PE20050665A1 (es)	2005-11-02	ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
WO2005072277A3 (en)	2007-10-04	Amidated parathyroid hormone fragments and uses thereof
WO2004083241A3 (en)	2005-03-31	Btc-interacting proteins and use thereof
GB9711389D0 (en)	1997-07-30	Bacterial pheromones and uses therefor
IT1294967B1 (it)	1999-04-23	Composizione immunogenica da tlp
TR200002611T2 (tr)	2000-12-21	Beta-lipotropin ve kullanımları
BR9809419A (pt)	2000-06-13	Combinação de antiácido e papaìna
ES2176642T3 (es)	2002-12-01	Utilizacion de la sulbutiamina para la obtencion de composiciones farmaceuticas utiles en el tratamiento de ciertos t rastornos psicomotores y psicointelectuales.